CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 27, 2017--
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on August 3,
2017 at 8:00 a.m. ET to discuss second quarter 2017 results and provide
a general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
62118608. To join the live webcast, please visit the “Investors and
Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning
approximately two hours after the event and will be archived for
approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. Seres’ lead
program, SER-109, has obtained Breakthrough and Orphan Drug designations
from the US Food and Drug Administration and is in Phase 3 development
for multiply recurrent C. difficile infection. Seres’ clinical candidate
SER-287 is being evaluated in a Phase 1b study in patients with
mild-to-moderate ulcerative colitis. Seres is also developing SER-262,
the first ever synthetic microbiome therapeutic candidate, in a Phase 1b
study in patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727005125/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Seres Therapeutics, Inc.
Head of Investor Relations and Corporate